Stifel resumes Starbucks stock coverage with buy rating, $115 target

Stifel resumed coverage of Starbucks with a Buy rating and a $115 price target, about 9% above the cited $105.41 share price. It expects comparable-sales momentum and cost savings to support another year of double-digit EBITDA growth, while citing lease-adjusted leverage below 3x and a 2.4% dividend yield. Analyst views are generally positive but varied, and InvestingPro describes the shares as overvalued relative to its Fair Value.

Analysis

The actionable question is whether operating improvement can outrun the multiple risk. A recovery built on comparable-sales leverage and cost savings could lift EBITDA without relying solely on expansion, but labor and coffeehouse-experience spending may absorb more of that benefit than the bullish case assumes. At the cited valuation, the market has limited tolerance for a sales or margin miss; the dividend is not a reliable valuation floor. Stifel’s target implies only modest upside from the quoted share price, while the wider range of analyst targets signals materially different views of execution—not independent proof that earnings are turning. The more important confirmation is reported North American comparable sales alongside operating-margin progression, not another target change.

Over the next 1–3 months, watch company guidance and results for evidence that traffic and sales gains are translating into margins after labor investment. Over 6–18 months, sustained execution could support earnings growth and reduce reliance on cost actions; failure would expose the shares to both estimate cuts and multiple compression. The thesis weakens if comparable sales deteriorate, margin recovery stalls, or management indicates labor and experience investments are outpacing sales leverage. Conversely, repeated margin improvement with healthy traffic would validate the recovery. No strong immediate catalyst or clear mispricing is established by this analyst note alone.

Key Decisions for Investors

• Do not chase SBUX solely on the coverage resumption. Treat it as a confirmation setup: consider adding only after reported comparable-sales momentum is accompanied by operating-margin improvement.
• For an existing position, keep exposure conditional on execution; reassess if comparable sales weaken or margins fail to improve despite cost savings. The dividend should not be treated as a downside hedge.
• Monitor the next results and guidance for traffic trends, labor and experience spending, and North American operating margins. These data are needed to distinguish durable self-funded recovery from a sales-led thesis that is not converting into earnings.